|Description||Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.|
|Related CAS||267243-28-7 (Free base)|
|Current Developer||Pfizer, Inc.|
Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...
Pyrotinib, also known as SHR-1258, is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Upon oral administration, pyroti...
ZD-4190, a substituted 4-anilinoquinazoline, is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of e...
EGCG, also called Epigallocatechin gallate, under the IUPAC name [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxy...
Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth ...
HKI 357 is a potent and irreversible dual inhibitor of ErbB2 (HER2) and EGFR (IC50 = 33 and 34 nM, respectively). It inhibits EGFR autophosphorylation and proli...
PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung can...
AV-412 is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibit...